Integral Diagnostics Limited
ACN 130 832 816

T | +61 3 5339 0704
E | info@idxgroup.com.au

Level 2, 288 Victoria Parade
East Melbourne VIC 3002

PO Box 551
East Melbourne VIC 8002

www.integraldiagnostics.com.au

ASX & MEDIA RELEASE

FY26 Results

Integral Diagnostics Reports FY26 Results

- **Strong revenue growth with improved Operating EBITDA margin of 20.9%, in line with guidance**
- **Increase in Operating NPAT by 50.1% to $47.4m**
- **Strong Operating Diluted EPS growth of 23.6%, reflecting a full year's weighting of shares on issue**
- **Continued strong cash flow conversion of 82.0%**
- **Fully franked final dividend of 6.0 cents per share (total FY26 fully franked dividend of 9.3 cents per share), representing a 50% increase on the prior comparable period**
- **Balance sheet remains strong with reduced leverage of 2.3x, in line with guidance**

25 August 2026

Integral Diagnostics Limited (ASX: IDX) today announces its financial results for the year ended 30 June 2026 (FY26), which are consistent with the unaudited preliminary FY26 results released on 10 August 2026.

Key FY26 Results[1]

- Revenue and other income of $788.7m, up 25.6%
- Operating EBITDA of $164.8m, up 30.3%
- Operating EBITDA margin of 20.9%, up 80 bps from 20.1%
- Operating NPAT of $47.4m, up 50.1%
- Statutory NPAT of $22.0m, includes $25.4m relating to transaction and integration costs, restructuring costs, remeasurement of contingent consideration liabilities, and share based expenses relating to transaction and integration activities, net of tax
- Operating free cash flow of $106.4m, up 30.7%
- Net debt to Operating EBITDA of 2.3x, down from 2.6x at 30 June 2025
- Operating diluted EPS of 12.6 cents, up 23.6%
- Fully franked final dividend of 6.0 cents per share, up 50.0%, declared and payable on 2 October 2026 (total FY26 fully franked dividend of 9.3 cents per share)

[1] FY25 comparative results include operations from Capitol Health Limited (Capitol) from 20 December 2024, being the date of acquisition, through to 30 June 2025.

Group Summary

AUD$ million	FY26	FY25[1]	Change $	Change %
Profitability				
Statutory NPAT[2]	22.0	2.8	19.2	677.4%
Revenue	788.7	628.0	160.7	25.6%
Operating EBITDA ($)	164.8	126.5	38.3	30.3%
Operating EBITDA margin (%)	20.9%	20.1%		0.8%
Operating EBITA ($)	97.1	70.0	27.1	38.8%
Operating EBITA margin (%)	12.3%	11.1%		1.2%
Operating NPAT	47.4	31.6	15.8	50.1%
Operating diluted EPS (cents)	12.6	10.2	2.4	23.6%
Cash Flow & Capital Management				
Operating free cash flow	106.4	81.4	25.0	30.7%
Operating free cash flow conversion, prior to replacement capital expenditure	82.0%	86.5%		
Dividends declared per share (cents)	6.0	4.0	2.0	50.0%
Net debt (pre-AASB 16)	298.9	298.0	0.9	0.3%
Net debt / EBITDA (pre-AASB 16)[3]	2.3x	2.6x		
Equity	681.5	692.0	(10.5)	(1.5%)

1 FY25 comparative results include operations from Capitol from 20 December 2024, being the date of acquisition, through to 30 June 2025.

2 Comparative information for the year ended 30 June 2025 has been restated to reflect the finalisation of fair value adjustments arising from the acquisition of Capitol Health on 20 December 2024. This restatement resulted in a $2.0m reduction in Statutory NPAT. As this adjustment is considered a non-operating item, FY25 operational results remain unchanged.

3 Based on net debt excluding the impact of lease liabilities of $298.9m (FY25: $298.0m). LTM EBITDA of $129.6m (FY25: $116.4m) excludes any impact of AASB 16 and includes trailing LTM EBITDA for acquisitions. This approach is consistent with banking covenant requirements.

Result Commentary

Jason Martinez, Managing Director and CEO of IDX said *"IDX delivered a strong FY26 result, with solid revenue growth, improved margins and disciplined execution across the business, resulting in performance in line with our guidance. This translated into enhanced shareholder returns, with operating diluted EPS increasing 23.6% and a fully franked final dividend of 6.0 cents per share, up 50.0% on the prior year.*

The strength of the result was also reflected in operating free cash flow growth of 30.7% and a further reduction in leverage to 2.3x, reinforcing the quality of our earnings, financial discipline and the strength of our balance sheet.

Throughout the year, we continued to make progress against our strategic priorities, including the successful integration of Capitol, ongoing investment in our network and the continued growth of our teleradiology platform, IDXt. Pleasingly, we also maintained industry-leading patient satisfaction outcomes while supporting more patients and referrers across Australia and New Zealand.

Looking ahead, IDX is well positioned to benefit from favourable industry fundamentals, including increasing demand for diagnostic imaging services, growth in higher-value modalities and advances in technology. Our scale, clinical capability and ongoing focus on operational excellence provide a strong foundation to continue improving patient access, supporting our referrers and delivering sustainable growth, improvement in productivity, margin expansion and long-term value for shareholders."

Key FY26 Results Highlights

Solid revenue growth with improved Operating EBITDA margin

- Solid revenue growth driven by growth in patient volumes, Medicare indexation and continued favourable mix impact, being 7.0%(3) on a constant currency basis excluding closed or sold sites.
- Medicare indexation increase of 2.4% effective 1 July 2025 on all diagnostic imaging services (excluding PET nuclear imaging services).
- Organic revenue from all sources in Australia grew 7.4%(2)(3) compared to Medicare growth of 9.4%(3) over the course of FY26 comprised of:
  - 8.9%(3) growth for the legacy IDX business, reflecting strong growth supported by MRI de-regulation and the National Lung Cancer Screening Program, and further closing the gap to Medicare growth vs the prior comparative period.
  - 5.4%(2)(3) growth for the legacy Capitol business, reflecting lower growth of GP attendances and referrals.
- Average fees per exam (including reporting contracts) in Australia increased by 6.5% in FY26, reflective of Medicare indexation and an on-going move to the higher end CT, MRI and PET scan modalities.
- Organic revenue in New Zealand grew 2.1%(3)(4), on a constant currency basis.
- Improved Group Operating EBITDA margin of 20.9%, up 80 bps vs FY25.
- Margin growth underpinned by operational cost leverage and synergies of $14m+ achieved from the merger with Capitol Health.

Merger integration is largely complete

- Organisation structure further refined to support focus on patients and drive the business.
- Annual ongoing synergies achieved of $14.0m+ (compared to at least $10.0m expected at time of merger).
- Group procurement function driving cost savings above initial synergy projections.
- Increased teleradiology scale, with contribution from Capitol radiologists.
- Strong employee engagement scores recorded in annual July survey.

Balance sheet and cash flows remain strong with reduced leverage in line with guidance

- At 30 June 2026 the Group held cash of $51.3m. In addition, the Group has committed facilities of $467.4m, of which $117.0m remains undrawn (subject to banking facility financial covenant compliance), with a further $200.0m in uncommitted facilities. The Group is in compliance with all covenants under the debt facility.

---

[2] Calculated based on FY25 pro forma revenue for the Group, assuming a Capitol acquisition date of 1 July 2024 and adjusted for the revenue contribution of four closed sites and the sale of the Melton site.

[3] Adjusted for working days - average number of working days in FY26 was 251, versus 250 in the prior comparative period.

[4] Adjusted for one closed site.

- Net debt increased slightly by $0.9m to $298.9m (FY25: $298.0m), with the Group's net debt to equity ratio at 30 June 2026 being 43.9% (FY25: 42.9%).
- Net Debt to EBITDA of 2.3x at 30 June 2026 (down vs 2.6x at 30 June 2025), in line with the Group's target range of 2.0x to 2.5x, projected to continue to trend down further over time.
- Reduced weighted average interest rate on core debt facility of 5.36% (vs 6.24% at 30 June 2025), with 51.2% of gross debt hedged effective late December at favourable interest rate compared to current BBSY rate.
- In FY26 capital expenditure totalled $49.8m, with $21.0m relating to growth initiatives including investment in brownfield and greenfield sites.

Dividend

A fully franked final dividend of 6.0 cents per share has been declared, up 50.0% vs the prior corresponding period. The Dividend Reinvestment Plan (DRP) will again be available. Fully franked dividends of 9.3 cents per share (FY25: 6.5 cents per share) totalling $34.6m have been paid or declared for FY26.

Key dates for the final dividend are:

Record date	31 August 2026
Final DRP election date	1 September 2026
Payment and issue date	2 October 2026

Company Outlook

The Company's strategic focus in FY27 and beyond will be to build from strong FY26 delivery, focussing on disciplined growth, improving productivity and long term value creation through the following key drivers:

- Core growth and optimisation – execute within the platform
- Network expansion – disciplined, selective growth
- People and culture – capacity, capability and culture
- Transformation and innovation – better pathways and productivity

Outcomes we are focussed on:

- Sustainable revenue growth
- EBITDA margin improvement >21.0%
- Increased productivity and capacity
- Improved patient access
- De-gearing

Group FY27 replacement and growth capex is expected to be between $50.0m to $60.0m.

Investor and Analyst Conference Call

Integral Diagnostics' Managing Director & Chief Executive Officer, Jason Martinez, and Chief Financial Officer, Craig White, will be holding an investor and analyst conference call at 11.00am AEDT today.

For those wishing to dial into the call, please register for the call through the following link:

https://s1.c-conf.com/diamondpass/10056165-zch721.html

Alternatively, at the time of the call, dial your respective number below and provide the conference ID 10052174 to the operator, noting there may be wait times:

AUSTRALIA: 1800 809 971

AUSTRALIA Local: 02 9007 3187

NEW ZEALAND: 0800 453 055

AUCKLAND Local: +64 9 929 1687

For further details contact

Integral Diagnostics
John Merity
Company Secretary
Tel: 0418 817 255
Email: jmerity@idxgroup.com.au

Authorised for lodgement by the Integral Diagnostics Board of Directors.

About IDX:

Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. IDX employs some of Australasia's leading radiologists and diagnostic imaging specialists in a unique medical leadership model that ensures quality patient care, service and access. Good medicine is good business. For more information, please visit www.integraldiagnostics.com.au/.

FORWARD-LOOKING STATEMENTS

This announcement contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of IDX, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of IDX's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of IDX or its representatives assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to IDX as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of IDX or its representatives undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.